NCT04191577已完成2 期
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 136
- 试验地点
- 21
- 主要终点
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Study Drug
研究概览
简要总结
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
详细描述
Approximately 135 male and female subjects with Parkinson's disease, on a stable dosage of levodopa but with an average of ≥ 2 h total OFF time/day and not less than 1 h per day, will be enrolled. Following baseline safety and efficacy assessments, subjects will be randomized to receive once-daily doses of either low-dose CVN424, high-dose CVN424, or matching placebo. All subjects not randomized to placebo will initiate treatment with a low-dose of CVN424 on Day 1; the low-dose arm will continue to receive their low dose each day, while the high-dose arm will increase their daily dosage to the high-dose CVN424 beginning on Day 8 ±2 days and continuing thereafter. Study drug will be self-administered each morning as an oral suspension. Subjects will continue their other PD medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult who is 30 to 80 years of age inclusive at study entry.
- •Has idiopathic Parkinson's disease, Hoehn and Yahr stages 2-4, and is on a stable dosage of levodopa.
- •Experiences an average of at least 2 h total OFF time/day, and at least 1 h each day, per Patient Motor Diary over 2 days during Screening assessment.
- •The subject signs and dates a written informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •Has atypical parkinsonism, severe disabling dyskinesia, or severe motor fluctuations that the investigator considers likely to interfere with study participation or assessments, or history of implant for Deep Brain Stimulation.
- •Poor concordance (<75%) of self-report with site rater on in-clinic Screening period Patient Motor Diary. Subjects with low concordance may be retested after further instruction, at investigator's discretion.
- •Screening period Patient Motor Diary scored at-home over 2 days demonstrates unacceptable quality of the diary, with more than 4 errors per day. (Assistance from caregivers is permitted if they also will be providing assistance with home Patient Motor Diary entries for Day 15 and 27 efficacy assessments.) Subjects with more than 4 errors per day may be retested after further instruction, at investigator's discretion.
- •Body mass index (BMI) at Screening <18.0 or >35.0 kg/m2, inclusive.
- •Subject has evidence of Clinically significant neurologic or other disorder or impairment that, in opinion of Investigator, is reasonably expected to impact the ability of the subject to participate or to confound the study results.
- •Subject has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, any surgical intervention known to impact absorption [e.g., bariatric surgery or bowel resection]).
- •Subject has a history of cancer or other malignancy, with the exception of low-grade cervical intraepithelial neoplasia, low-grade (low-risk) prostate cancer, or 5-year cancer-free survivors of basal or squamous cell carcinoma, higher-grade cervical intraepithelial neoplasia or prostate cancer.
- •Has a history of human immunodeficiency virus (HIV) infection.
- •Subject has a supine blood pressure outside the ranges of 80 to 160 mm Hg for systolic and 50 to 100 mm Hg for diastolic, confirmed with up to two repeat tests, at the Screening Visit; or symptomatic orthostatic hypotension, in the opinion of the investigator.
- •Subject has a resting heart rate outside the range 50 to 100 bpm, confirmed with up to two repeat tests, at the Screening Visit.
- •Positive urine result for illegal drugs (except cannabis) at Screening, or history of illegal drug use (except cannabis) or alcohol abuse within 1 year prior to the Screening Visit.
- •Subject has received any investigational compound (defined as a drug that has not been FDA-approved) within 30 days prior to the first dose of study medication, or within 5 half-lives of the investigational compound, whichever is greater.
- •Subject has, within the prior month, ingested any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table as listed in Table
- •Male subjects who do not agree to all the following rules: when sexually active with female partner(s) of childbearing potential during the study and for 12 weeks after the last dose of study drug: a) use an acceptable method of birth control (condom with spermicide or surgical sterilization) and b) refrain from sexual activity with female partners who do not use an acceptable method of birth control. Barrier contraception (condom with spermicide) must be used by all male subjects who were not surgically sterilized at least 90 days prior to screening. Male subjects must also agree to refrain from sperm donation during the study and until 12 weeks after the last dose of study drug.
- •Female subjects who are pregnant or breastfeeding or plan to become pregnant or donate ova during the study or for 30 days after the last dose of study drug. Women of childbearing potential (WOCBP) also must be practicing an adequate method of birth control (e.g., oral or parenteral contraceptives, intrauterine device, barrier, abstinence).
- •Risk of suicide according to the investigator's clinical judgment or has made a suicide attempt in the previous 3 years.
- •Subject is a study site employee or an immediate family member of a study site employee
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo to be administered once daily.
干预措施: Placebo (Drug)
CVN424 (Low Dose)
Active Comparator
Low dose of CVN424 to be administered once daily.
干预措施: CVN424 Low Dose (Drug)
CVN424 (High Dose)
Active Comparator
Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
干预措施: CVN424 High Dose (Drug)
结局指标
主要结局
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Study Drug
时间窗: Up to Day 35
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAEs are defined as any event with onset during or after the first dose of study treatment (active or placebo).
次要结局
- Percentage of Participants With Clinically Significant Abnormal Laboratory Parameters(Up to Day 35)
- Percentage of Participants With Clinically Significant Abnormal Vital Signs(Up to Day 35)
- Percentage of Participants With Clinically Significant Changes 12-Lead Electrocardiogram (ECG) Findings(Up to Day 35)
- Change From Baseline in 2-day Average OFF Time(Baseline and at Day 27)
研究者
研究点 (21)
Loading locations...
相似试验
撤回
2 期
Study of CAD-1883 for Spinocerebellar AtaxiaSpinocerebellar AtaxiasSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 7Spinocerebellar Ataxia Type 8Spinocerebellar Ataxia Type 10Spinocerebellar Ataxia Type 17ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1Spinocerebellar Ataxia Type 3NCT04301284Cadent Therapeutics
已完成
2 期
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisPsoriasisNCT05096364Akeso251
已完成
2 期
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated InfluenzaInfluenzaNCT01068912MDVI, LLC530
已完成
2 期
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPFIdiopathic Pulmonary FibrosisNCT05483907Bridge Biotherapeutics, Inc.129
终止
2 期
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic DermatitisAtopic DermatitisNCT05155085Allakos Inc.131
相关资讯
Five Promising Therapeutic Candidates in Parkinson's Disease Clinical Pipeline- Ambroxol, a repurposed cough suppressant, shows potential as a disease-modifying therapy for Parkinson's by enhancing lysosomal function and clearing α-synuclein aggregates, with the GREAT trial currently evaluating its efficacy.
- Novel anti-inflammatory compounds targeting the NLRP3 inflammasome, including Inzomelid and NT-0796, are advancing through clinical trials as potential disease-modifying agents that could slow neurodegeneration in Parkinson's disease.
- Gene therapy approach AAV2-GDNF and innovative non-dopaminergic treatments like Solangepras and Glovadalen represent significant advances in the therapeutic pipeline, offering potential for durable neuroprotection and improved symptom management with fewer side effects.last yearCerevance's Solengepras Fails Primary Endpoint in Phase II Parkinson's Trial, Shows Promise for Non-Motor Symptoms• Cerevance's GPR6 antagonist solengepras failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, showing only a small, non-significant improvement versus placebo.
• Despite missing the primary endpoint, solengepras demonstrated promising trends in improving non-motor symptoms and functional impairments, with fewer adverse events related to non-motor symptoms reported in the treatment arm.
• The company is advancing solengepras in the pivotal Phase III ARISE trial as an adjunctive therapy to levodopa for Parkinson's patients with motor fluctuations, with topline data expected in the first half of 2026.last yearPhase 3 Trial of Solengepras for Parkinson's Disease Begins Dosing• Cerevance's solengepras, an oral GPR6 inhibitor, has entered a Phase 3 clinical trial (ARISE) as an add-on therapy for Parkinson's disease.
• The ARISE trial (NCT06553027) will evaluate solengepras' efficacy in reducing off-time in Parkinson's patients already treated with levodopa.
• Solengepras aims to improve motor control and reduce dyskinesia by modulating brain circuits without directly relying on dopamine pathways.
• Topline data from the ARISE trial is expected in the first half of 2026, with a focus on changes in daily off-time after 12 weeks of treatment.last year